About mirvetuximab soravtansine
            
            Class: | Antibody-drug conjugate (ADC)  
Use: | Treatment of adult patients with platinum-resistant ovarian cancer that is folate receptor alpha (FRα) positive, who have received one or more prior systemic therapies.  
Adult dose: | 6 mg/m² administered as an intravenous infusion over 60 minutes once every three weeks.  
Pediatric dose: | Safety and efficacy in pediatric patients have not been established; not recommended for use in pediatric populations.  
Side effects: | Common side effects in
         
        
            
                
                
                    
                        Drug Class
                    
                    Antibody-drug conjugate (ADC)
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adult patients with platinum-resistant ovarian cancer that is folate receptor alpha (FRα) positive, who have received one or more prior systemic therapies.
                 
                
                
                    
                        Storage Requirements
                    
                    Store in the original carton at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light.
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: AbbVie Deutschland GmbH & Co. KG [Ludwigshafen;Germany], Germany
                    
                    
                    Package Size
                    1 Glass Vial (20 mL)
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 32140.50
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        6 mg/m² administered as an intravenous infusion over 60 minutes once every three weeks.
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy in pediatric patients have not been established; not recommended for use in pediatric populations.
                    
                 
                
                
                    
                        Side Effects
                    
                    Common side effects include nausea, fatigue, vomiting, diarrhea, abdominal pain, and ocular toxicity (including blurred vision and dry eyes).
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to mirvetuximab soravtansine or any component of the formulation; pregnancy (due to potential harm to the fetus).
         
        
        
            
                Important Warnings
            
            Risk of ocular toxicity; monitor for visual disturbances. Risk of infusion-related reactions; premedication may be required. Use caution in patients with hepatic impairment.
         
        
        
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.